Conference focuses on implants

ICOI to host its annual Winter Implant Symposium in Orlando

By ICOI Staff

Orlando and the surrounding Central Florida region is a favorite destination among travelers from around the globe. Join us there on Jan. 11-13 for the ICOI Winter Implant Symposium — a spectacular program designed by ICOI President Dr. Michael Pikos. Serving as our host hotel, the Orlando World Center Marriott offers amazing on-site amenities as well as a shuttle service to nearby amusement parks.

The theme for this meeting will be “Maxillary Arch Reconstruction: Single Tooth to Full Arch.” Scientific Program Chair Pikos, from Trinity, Fla., has assembled a talented group of experienced and enthusiastic, private practice and academic-based clinicians who will share their respective wealth of knowledge in a friendly and scientific environment.

The first day will feature a full afternoon podium devoted to our “Young Implantologists.” Quickly becoming a highlight of the ICOI meetings, this afternoon session on Thursday, Jan. 11, will showcase the fresh ideas and talents from our

• See ICOI, page A4

The International Congress of Oral Implantologists will host its Winter Implant Symposium in Orlando this January.

Photo/www.freeimages.com

25th AAOMS Dental Implant Conference to continue its educational tradition

By AAOMS Staff

The American Association of Oral and Maxillofacial Surgeons (AAOMS) will host its 25th Dental Implant Conference — a premier dental implant educational event featuring an internationally renowned faculty of experts — from Nov. 30 to Dec. 2 in Chicago, Ill.

More than 1,000 oral and maxillofacial surgeons, their staff and restorative dentists will gather to enhance their knowledge of dental implants, which offer patients a long-term solution to missing teeth. The event caters to the entire dental implant team.

By attending the three days of innovative research and procedural courses, participants can elevate their implant practice. Session topics — taught by more than 30 speakers — range from replacing congenital missing teeth to effectively applying digital technology in a practice.

Highlights of the preconference sessions and the intensive educational
By JOMS Staff

Botulinum toxin A, or Botox, is a protein made from bacteria that, when injected, stops nerve signals that command muscles to contract—resulting in a months-long decrease in muscle activity. It has been used to treat conditions such as muscle spasms, facial wrinkles, migraines and excessive sweating.

To determine the therapy’s safety and effectiveness in treating stubborn jaw muscle pain, researchers conducted a retrospective review of 116 patients. The patients underwent at least two Botox injection cycles for refractory masticatory myalgia—pain in the muscles used for chewing—that had not responded to other therapies.

Among the participants, 16.4 percent had moderate relief for 8.7 weeks on average, and 29.6 percent had no or minimal relief for 13 weeks on average. Another 4 percent reported at least one negative effect during the two injection cycles. Those who had significant pain relief had the largest number of adverse effects at 30.3 percent. The most common side effect was a decrease in the size of the masticatory muscle, possibly due to blocked release of a chemical that activates muscles, the study states. However, all of the negative effects were minor and brief, and full recovery occurred within 16 weeks.

Simultaneous use of opioid pain relievers was a predictor of no or minimal relief. Of the participants, 36 percent were using a long-term opioid therapy. Long-term opioid use can result in opioid-induced hyperalgesia—a painful response to the medications—and having chronic pain disorders can lead to diminished effect of pain relievers, researchers wrote. “Together, these factors may result in poor outcome and response to therapy,” they said.

The authors concluded, “Effectiveness, safety, and predictors of response to botulinum toxin A in refractory masticatory myalgia: A retrospective study” are all from the Department of Oral and Maxillofacial Surgery at Massachusetts General Hospital; David A. Keith, DMD, BDS, professor at Harvard School of Dental Medicine; Steven J. Scrivani, DDS, DMD, chief, Division of Oral and Maxillofacial Pain, Nicole Holland, DDS, MS, and Shehryar N. Khawaja, BDS, MS, postgraduate Fellow at Harvard School of Dental Medicine.

The full article can be accessed at www.joms.org/article/S0278-2391(17)30116-7/#fulltext.

About JOMS

The Journal of Oral and Maxillofacial Surgery is published by the American Association of Oral and Maxillofacial Surgeons to present to the dental and medical communities comprehensive coverage of new techniques, important developments and innovative ideas in oral and maxillofacial surgery. Practice-applicable articles help develop the methods used to handle dental/surgical trauma; facial injuries and deformities, TMD disorders, oral and head and neck cancer, jaw reconstruction, anesthesia and analgesia. The journal also includes specifics on new instruments and diagnostic equipment, and modern therapeutic drugs and devices.

A2

FROM PAGE 1

JOMS study: Botox can relieve jaw muscle pain

According to a study published in the November issue of the Journal of Oral and Maxillofacial Surgery, botulinum toxin A injections also may have pain-relieving properties.

By JOMS Staff

Botulinum toxin A, or Botox, is a protein made from bacteria that, when injected, stops nerve signals that command muscles to contract—resulting in a months-long decrease in muscle activity. It has been used to treat conditions such as muscle spasms, facial wrinkles, migraines and excessive sweating.

To determine the therapy’s safety and effectiveness in treating stubborn jaw muscle pain, researchers conducted a retrospective review of 116 patients. The patients underwent at least two Botox injection cycles for refractory masticatory myalgia—pain in the muscles used for chewing—that had not responded to other therapies.

Among the participants, 16.4 percent had moderate relief for 8.7 weeks on average, and 29.6 percent had no or minimal relief for 13 weeks on average. Another 4 percent reported at least one negative effect during the two injection cycles. Those who had significant pain relief had the largest number of adverse effects at 30.3 percent. The most common side effect was a decrease in the size of the masticatory muscle, possibly due to blocked release of a chemical that activates muscles, the study states. However, all of the negative effects were minor and brief, and full recovery occurred within 16 weeks.

Simultaneous use of opioid pain relievers was a predictor of no or minimal relief. Of the participants, 36 percent were using a long-term opioid therapy. Long-term opioid use can result in opioid-induced hyperalgesia—a painful response to the medications—and having chronic pain disorders can lead to diminished effect of pain relievers, researchers wrote. “Together, these factors may result in poor outcome and response to therapy,” they said.

The authors concluded, “Effectiveness, safety, and predictors of response to botulinum toxin A in refractory masticatory myalgia: A retrospective study” are all from the Department of Oral and Maxillofacial Surgery at Massachusetts General Hospital; David A. Keith, DMD, BDS, professor at Harvard School of Dental Medicine; Steven J. Scrivani, DDS, DMD, chief, Division of Oral and Maxillofacial Pain, Nicole Holland, DDS, MS, and Shehryar N. Khawaja, BDS, MS, postgraduate Fellow at Harvard School of Dental Medicine.

The full article can be accessed at www.joms.org/article/S0278-2391(17)30116-7/#fulltext.

About JOMS

The Journal of Oral and Maxillofacial Surgery is published by the American Association of Oral and Maxillofacial Surgeons to present to the dental and medical communities comprehensive coverage of new techniques, important developments and innovative ideas in oral and maxillofacial surgery. Practice-applicable articles help develop the methods used to handle dental/surgical trauma; facial injuries and deformities, TMD disorders, oral and head and neck cancer, jaw reconstruction, anesthesia and analgesia. The journal also includes specifics on new instruments and diagnostic equipment, and modern therapeutic drugs and devices.